COVID-19 has delayed many elective procedures impacting patients, neurosurgeons and hospitals. ClearPoint Neuro is pleased to present you with the first in our series of ClearPoint TV Peer-to-Peer Webinars to share “best practices” among neurosurgery colleagues and help improve efficiency when you resume elective cases. Register Here
NewslettersSubscribe to our Newsletter
From Joe Burnett, President & CEO:
Welcome to the launch of our quarterly eNewsletter. The goal of this communication is to inform customers of important company events, product releases and updates. I will start by reassuring you that ClearPoint Neuro’s commitment to our hospital partners has been steadfast throughout this Global Pandemic. Since mid-March, whenever a neurosurgeon has needed us to support a case, our team has been there, often driving long distances when flights were unavailable, and staying with friends and family when hotels were shuttered. Despite the slow down of commercial activities, the financial position of our company has allowed us to retain 100% of our employees. Over the past three months we continued our ongoing product development activities and maintained our readiness to serve your patients now that procedures are resuming. Thanks for allowing us to support your patients and your teams during this difficult time. We can’t wait to meet you in person again soon.
ClearPoint Neuro is excited to announce the launch of the Inflexion Head Frame for customers in the U.S. and EU. Inflexion is designed for versatile pinning within diagnostic-only and intraoperative MRI environment. Patients can be pinned supine and flipped prone for an occipital approach.
We are proud to introduce the "Larson" Bladed Lancet, named after Dr. Paul Larson, Professor and Vice Chair of Neurological Surgery at UCSF. The lancet is intended to pierce or cut tissue during a neurosurgical procedure, allowing the surgeon to leave the dura closed after mounting the frames and use it to pierce a hole through the dura and pia right before insertion.
The ClearPoint 2.0 software, first introduced in the U.S. in 2018, has received CE mark for use in the EU. Our 2.0 Software is an optimal visualization platform that enables multiple minimally invasive neurosurgical procedures.
Matthew B. Klein has been appointed to ClearPoint Neuro’s Board of Directors. Dr. Klein, Chief Development Officer at PTC Therapeutics, Inc., is a veteran biotechnology company executive with extensive experience in drug discovery and development, and is a board-certified surgeon.